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Summary Withholding iron frompotentialpathogens is ahostdefense strategy. There is evidence
that iron overload per se compromises the ability of phagocytes to kill microorganisms. Several
hypotheses exist to explain the association of hemochromatosis with infection. A combination of
mechanisms likely contributes to the increase in susceptibility to infection in these patients. A
review of the current literature delineating various pathogens to which patients with hemochro-
matosis are potentially susceptible, and recent advances in the understanding of the association of
hemochromatosis with infection, are discussed.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Background
The association of hemochromatosis with certain organisms
has been well described. Over the years, several mechanisms
have been postulated to explain the association. However,
with rapid advances in the understanding of hemochroma-
tosis over the past two years, more data about the complex,
iron-dependent host—pathogen interactions are now avail-
able. There is no single source in which the various infections
seen in hemochromatosis, including viral infections, are
described in relation to pathogenesis.
Methods
This review has been formulated after careful scrutiny of the
medical literature for the period between 1940 and January* Corresponding author. Tel.: +1 304 234 8536; fax: +1 304 234 8293.
E-mail address: fkhan@ovrh.org (F.A. Khan).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.04.0072007, and describes the various infections and the postulated
mechanisms of this unique association.
Iron and host defense
A common factor in all infections is the ability of the invading
pathogen to propagate in host tissue. Little is known about
the alterations that occur in pathogenic bacteria as they
adapt to the host environment and multiply in vivo. One of
the most notable aspects of the host environment and its
effects on bacterial growth concerns the availability of iron.
Iron is absorbed in the duodenum by enterocytes and trans-
ferred to the plasma. There it is bound by the high-affinity
iron-binding glycoproteins — transferrin and structurally
related protein lactoferrin.
Liver parenchymal tissue is especially rich in transferrin
receptors and stores large quantities of iron. Inmuscle tissue,
iron is used to make myoglobin, and in bone marrow, ery-
throcytes use it to make hemoglobin. Circulating red bloodPublished by Elsevier Ltd. All rights reserved.
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they become senescent, red blood cells are engulfed by
reticuloendothelial macrophages, which make their iron
available for redistribution to other tissues via transferrin.
Transferrin has extremely high affinity for iron. This coupled
with the fact that two-thirds of the iron binding sites of the
protein are normally unoccupied, essentially eliminates free
iron from plasma and extracellular tissues. Although there is
an abundance of iron present in body fluids, the amount of
free iron is very small to sustain bacterial growth.1 In addi-
tion, during infections the host reduces the total amount of
iron bound to serum transferrin.2 Withholding iron from
potential pathogens is an important host defense strategy.
Moreover both transferrin and lactoferrin are bacteriostatic
in vitro for a number of bacteria. Lactoferrin is a prominent
component of the granules of polymorphonuclear leukocytes.
The protein is released at high concentrations by the cells in
areas of infection. However, despite these host mechanisms,
pathogenic bacteria manage to multiply successfully in vivo
to establish an infection. In contrast, a state of iron excess in
hereditary hemochromatosis has different implications,
since it involves preferential iron loading of the parenchymal
cells and not the reticuloendothelial system, which in turn
hinders the growth of many intracellular organisms including
Mycobacterium tuberculosis, Salmonella typhi, and Chlamy-
dia pneumoniae.3,4
Acquisition of iron by microorganisms
To obtain host iron, successful pathogens with a few excep-
tions, use one or more of the following strategies to adapt to
the iron-restricted environment:1 (1) proteolytic cleavage of
iron-binding glycoprotein, releasing iron; (2) reduction of
Fe+++ complex to Fe++ complex and release of Fe++ from
the glycoprotein through interaction between receptors on
the bacterial cell surface and the Fe+++ glycoprotein com-
plex, in a manner analogous to the reaction between trans-
ferrin and erythrocyte; or (3) by producing low molecular
weight iron-chelating compounds known as siderophores,
which are able to remove iron from Fe+++ glycoprotein com-
plex and deliver it to the bacterial cell.
The list of infectious disease agents whose virulence is
enhanced by iron continues to increase (Table 1).5 These
pathogens include bacteria (Gram-negative and Gram-posi-
tive), fungi, and viruses.
Escherichia coli has been extensively studied and found to
have the ability to obtain iron via siderophores. E. coli speci-
fically is known to secrete enterobactin under conditions ofTable 1 Organisms whose growth in body fluids, cells, tissues, and
Fungi Candida, Cryptococcus,
Aspergillus, Pneumocyst
Protozoa Entamoeba, Leishmania
Gram-positive and acid-fast bacteria Bacillus, clostridia, cory
staphylococci, streptoco
Gram-negative bacteria Acinetobacter, Aeromon
Ehrlichia, Enterobacter,
Pasteurella, Proteus, Ps
Viruses Hepatitis B and C, cytom
Modified, with permission, from Weinberg ED. Iron loading and diseaseiron restriction.6,7 Similarly Vibrio has the ability to acquire
iron from its host by the production of siderophores and by
degradation of heme-containing compounds by proteolytic
enzymes.6,8—11 In contrast, Yersinia species are not able to
produce their own siderophores, but possess receptors for
iron—siderophore complexes on their surface, which enable
them to utilize siderophores synthesized by other bac-
teria.12,13 Therefore when patients with iron overload are
treated with chelating agents like deferoxamine (a sidero-
phore produced by Streptomyces pilosus), Yersinia may
use this exogenous siderophore to acquire iron.14 Listeria
monocytogenes as a pathogen requires iron for growth within
phagocytic cells and virulence expression.15 Weakened cell-
mediated immunity from iron overload16 is also likely linked to
the increased virulence of L. monocytogenes in patients with
hemochromatosis. Various studies, including experimental
studies in mice, have suggested that excess iron may enhance
the growth of M. tuberculosis and worsen the outcome of
human tuberculosis.17 The association of Tropherymawhippe-
lii with iron overload states has also been described.18 Ple-
siomonas shigelloides has been shown to produce a beta-
hemolysin, which is thought to play a role in iron acquisition
in vivo via the lysis of erythrocytes.19 Gemella haemolysans,
which is a member of the genus Gemella, previously included
under Neisseria species, may hypothetically, like certain iso-
lates ofNeisseria, use heminor hemoglobin as an iron source,20
or produce siderophores.21
Data on the ability of fungal pathogens to sequester iron in
vivo are not as well described and neither is this aspect well
researched. From what we do know, Rhizopus species have
been recognized in patients who have undergone treatment
of iron overload with deferoxamine,22 and iron overload in
the absence of deferoxamine therapy has also been linked
with zygomycosis.23 Interestingly diabetic ketoacidosis and
zygomycosis have been associated with iron metabolism;
acidosis may lead to decreased binding of iron by transferrin
and hence release of iron to be used by Rhizopus species.24
Hissen et al. have recently shown that Aspergillus fumigatus
survival in human serum in vitro involves proteolytic degra-
dation and siderophore-mediated removal of iron from trans-
ferrin.25
Evidence confirming the persistence and resistance to
treatment of viral hepatitis in the presence of excess iron is
rapidly mounting.26 It is now apparent that excess iron
enhances fibrogenic pathways and may act as a co-carcino-
gen or promoter of hepatocellular carcinoma, may worsen
the clinical course of HCV infection by causing oxidant stress
in nonparenchymal cells, and lead to the irreversibleintact vertebrate hosts is known to be stimulated by excess iron
Histoplasma, Paracoccidioides, Rhizopus, Trichosporon,
is
, Naegleria, Plasmodium, Toxoplasma, Trypanosoma
nebacteria, Erysipelothrix, Listeria, mycobacteria,
cci, Gemella
as, Alcaligenes, Capnocytophaga, Campylobacter, Chlamydia,
Escherichia, Klebsiella, Legionella, Moraxella, Neisseria,
eudomonas, Plesiomonas, Shigella, Vibrio, Yersinia
egalovirus, parvovirus, HIV
surveillance. Emerg Infect Dis 1999;5:346—52.
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hepatic fibrosis.27,28 Human cytomegalovirus protein US2
interferes with the expression of the hemochromatosis
gene, HFE.29 An increase in the cellular iron pool by down-
regulating HFE expression may promote the persistence of
viruses in general. It has also been shown that excess iron
decreases the viability of HIV-infected cells, increases p24
levels, and elevates the activity of reverse transcriptase,
indicating that iron overload associated with HIV infection is
detrimental to host cell responses against viral infection.30
Blumberg et al.were the pioneers in describing a role for iron
in the modulation of hepatitis B virus. They found that
patients with higher levels of serum iron or ferritin were
less likely to achieve spontaneous recovery after acute HBV
infection.31
Hemochromatosis
Hemochromatosis exists both in primary and secondary
forms. Primary or hereditary hemochromatosis (HH) is the
most common inherited disease in Caucasians. It results from
inheritance of an abnormal gene at a locus on the short arm of
chromosome 6 near the HLA locus (6p21). There is increased
absorption of iron across the gastrointestinal tract, which
leads to absorption of 3—4 mg/day of iron as opposed to
1—2 mg/day in normal individuals. The gene (HFE) is a class I
major histocompatibility complex (MHC) molecule that is
mutated in hereditary hemochromatosis. Patients who have
a chronic hematologic condition requiring multiple transfu-
sions of red blood cells develop a secondary form of hemo-
chromatosis.3,11,31—33
Hemochromatosis and infections
A review of medical literature on Medline for the period
January 1940 to January 2007, confirms McClatchie et al. as
being some of the first authors to describe the association of
sudden release of ferritin, previously shown to be a vasode-
pressor substance,34 into the circulation and shock in a
patient with hemochromatosis.35 Jones suggested a possible
link between infection and shock in hemochromatosis as one
patient was found to have E. coli bacteremia.36 Since that
time there have been numerous reports of patients with
hemochromatosis having increased susceptibility to infec-
tions.
Various infections caused by organisms including Vibrio
vulnificus,8,37 non-01 Vibrio cholerae,38 E. coli,36,39,40 Yersinia
enterocolitica13,41—43 and pseudotuberculosis,44 L.monocyto-
genes,45,46 P. shigelloides,47 G. haemolysans,48 cytomegalo-
virus,49 hepatitis B,50 C,51 and G virus,52 and HIV53 have been
reported in associationwithhemochromatosis. Fungi including
A. fumigatus54 and Rhizopus species23,55 have also been
described (Table 2). There is an article in German that
describes parvovirus in association with hemochromatosis.56
A multitude of problems likely contribute to the increased
susceptibility to infection in these patients. The very high
transferrin saturations attained in patients with iron overload
states compromise bacteriostatic properties. In the presence
of excessive iron, pathogens can much more readily procure
iron from molecules of transferrin. In such cases, even
microbial strains that are not ordinarily virulent can causeillness. In addition, iron overload compromises the ability of
phagocytic cells. Excess iron decreases chemotactic response
and enhances the ability of ingested microorganisms to pro-
liferate within the polymorphonuclear leukocytes (PMN) by
lowering bactericidal capacity.57,58 The toxicity of iron for
neutrophils may be due to the formation of excess oxygen
radicals, which alter phagocytosis through peroxidation of
neutrophil membrane lipids.59
Iron is a central regulator of immune cell proliferation
and function. All lymphocyte subsets, including B and T
lymphocytes and natural killer (NK) cells, depend on iron
uptake, the blockade of which leads to diminished prolif-
eration and differentiation of these cells. It is well estab-
lished that three subsets of CD4+ T-helper cells exist in man,
i.e., Th1, Th2 and Th3, each of which produces a set of
cytokines involved in immune regulation; for example, Th1
cytokines such as interferon-g (IFN-g) or tumor necrosis
factor-b (TNF-b) activate macrophages and contribute to
the formation of pro-inflammatory cytokines —TNF-a, inter-
leukin (IL)-1 or IL-6 — and the induction of the cytotoxic
immune effectormechanismofmacrophages. Iron loading of
macrophages results in the inhibition of IFN-g-mediated
pathways and hence they lose their ability to kill intracel-
lular pathogens, e.g., Legionella, Listeria, Ehrlichia. This
can partly be attributed to diminished production of nitric
oxide (NO) in the presence of iron.5,16,60
Hepcidin is a recently described cysteine-rich cationic
antimicrobial peptide secreted by the liver, with broad anti-
bacterial and antifungal actions,61,62 and is central to reg-
ulation of iron metabolism corresponding to the body’s iron
levels, i.e., increasing as they increase, e.g., in hemochro-
matosis, and vice versa. Specifically hepcidin levels rise with
infection or inflammation and fall with hypoxia or anemia.63
Decreased hepcidin leads to tissue iron overload, whereas
hepcidin overproduction leads to hypoferremia. In addition
to disrupting bacterial membranes, hepcidin provides an
inhospitable internal milieu for microbes that successfully
enter the bloodstream.64,65 It has recently been demon-
strated that inadequate expression of hepcidin in patients
with liver disease and functional impairment due to high iron
concentrations, may be associated with the increased sus-
ceptibility for infections in these patients.66 There is evi-
dence linking HFE with reduced iron uptake by the transferrin
receptor (TfR).
It is generally accepted that iron increases the formation
of hydroxyl radicals and other highly reactive oxidizing
molecules in biological systems. Experimental iron overload
in the rat model has been linked to lipid peroxidation in
mitochondria and microsomes, with deleterious effects on
the electron transport chain. Data suggest that iron causes or
enhances the hepatotoxicity and hepatocarcinogenecity
caused by chronic viral hepatitis.67 Enhanced hepatitis C
virus replication with iron overload has also been demon-
strated.68,69 Recent studies have indicated that, among
patients with chronic hepatitis C, there is an increased
prevalence of the C282Y mutation, the major mutation of
the HFE associated with hereditary hemochromato-
sis.26,67,70—72 This is responsible for downregulation of the
HFE expression and increasing the cellular iron pool. A similar
link between C282Y mutation and hepatitis B has also been
suggested by Sendi et al.50 Further confirmation of these
results is ongoing.
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Table 2 Various organisms and associated clinical diagnoses in patients with hemochromatosis
Organism Clinical scenario/infection [reference] Course/outcome
Plesiomonas shigelloides Septicemia [47] Twelve weeks of ofloxacin therapy instituted
due to intolerance to other antimicrobials
Gemella haemolysans Endocarditis [48] Two weeks of penicillin G/tobramycin with
sterilization of blood cultures
Escherichia coli Septic shock [36,39,40] Death after 24 hours of onset, despite
inotropic support
Meningitis [40] Meningitis responded to a 3 week/5 day course
of IV/IT moxalactam and gentamicin, respectively
Listeria monocytogenes Meningitis/endocarditis and
pericarditis [45]
Death
Vibrio vulnificus Fever, emesis diarrhea with
shock. There was history of
ingestion of raw oysters [37]
Death 7 hours after admission, despite
aggressive medical support
Non-O1 Vibrio cholerae (NOVC) Painful edema/erythema
left leg with bacteremia [38]
Forty-five day therapy with oral doxycycline
until resolution of cellulitis
Yersinia pseudotuberculosis Bacteremia with aldosterone
deficiency [44]
Multiple antimicrobials including erythromycin
Yersinia enterocolitica Septic yersinosis [14] Oral ciprofloxacin 750 mg bid for 6 months
Liver abscess [13,41,43] Oral ciprofloxacin 500 mg every 8 hours
for 23 days
Peritonitis [42] Oral doxycycline 400 mg every day for 8 weeks
Skin infection [43] Oral trimethoprim—sulfamethoxazole for
2 weeks after initial 9-day course of
IV chloramphenicol in case 1. Oral
doxycycline for 7 weeks in case 2.
Oral trimethoprim—sulfamethoxazole for 6 weeks
Mucor species, including Periorbital cellulitis [23] Patient in case with ‘Mucor spp’ underwent
right orbital exenteration. On postoperative
day 5, patient expired after a
hemorrhagic stroke
Cunninghamella bertholletiae Rhinocerebral mucormycosis [55] Patient died
Aspergillus fumigatus Peritonitis in patient who
underwent orthotopic liver
transplant [54]
Death secondary to liver failure
Hepatitis B, C and G HBV carrier [50] Severity of chronic hepatitis is linked with
degree of iron deposition. Patients with
chronic HBV and HCV have greater prevalence
of C282Y and C2824 hemochromatosis gene
mutations, respectively.
Chronic HCV [51] High prevalence of hepatitis G found
virus in hemochromatosisCryptogenic hepatitis [52]
Cytomegalovirus (CMV) Intrauterine CMV infection;
inclusions in hepatocytes, biliary
epithelial cells, renal tubular
epithelium. Concomitant
intracellular iron seen
in viscera [49]
1500 g cyanotic neonate died 1.5 hours after birth
Parvovirus Refractory anemia [56] 69-year-old woman with hemochromatosis
and myelodysplastic syndromeConclusions
The retrieval of iron is essential to bacterial survival and
represents a factor for which both host and pathogen com-
pete. Conditions including hemochromatosis, in which the
level of iron in serum is increased, compromise host defenses
and increase predisposition to various bacterial and non-bacterial infectious diseases. This excess iron burden does
not only help the propagation of pathogens, but also plays a
sentinel role in modifying the host immune mechanism,
specifically by impairment of cell-mediated immune
responses. Hepcidin has recently emerged as an important
bridge between innate immunity and iron metabolism and is
thought to be responsible for augmentation of the host
486 F.A. Khan et al.response to pathogens. Functional impairment of hepcidin
due to high iron concentrations has therefore been asso-
ciated with the increased susceptibility for infections in
these patients. It must be noted that most of the cases
reported in this review are based on case reports, but none-
theless may be helpful to physicians in expanding differential
diagnoses when faced with similar situations.
Often the diagnosis of hemochromatosis in these patients
is an incidental finding and physicians should therefore con-
sider evaluation for the diagnosis of hemochromatosis when
faced with infections caused by certain organisms as
described. Alternatively clinicians should consider various
pathogens in patients with hemochromatosis who present
with a febrile illness. Modulation of iron metabolism, includ-
ing use of recombinant hepcidin in patients with hemochro-
matosis and infectious diseases, is an area that warrants
further research.
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